|
|
Treatment with C1-INH
C1-INH treatment works by replacing the missing or dysfunctional C1-INH protein in patients with HAE. It can be directly administered to HAE patients to treat acute attacks or as short- and long-term prophylaxis.1
Berinert® is a highly purified human pasteurized nanofiltered C1-INH concentrate, indicated for use in the treatment of acute attacks of Hereditary Angioedema.11
Mechanism of action
Therapeutic C1-INH replaces the actions of natural C1-INH in patients with HAE. This leads to the inhibition of the classical complement cascade, the contact system, the blood clotting cascade and the fibrinolytic system. The result is the prevention of local inflammation by complement and bradykinin (BK).1 12-13 Because of its long half-life (a range 32—47 hours), this effect is sustained over the duration of an HAE attack and minimizes the risk of rebound edema.14-15
The mechanism of action of therapeutic C1-INH, which mimics the action of natural C1-INH.
|